These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 14703322)

  • 1. Limited effect of highly active antiretroviral therapy among HIV-positive injecting drug users on the population level.
    van Asten LC; Boufassa F; Schiffer V; Brettle RP; Robertson JR; Hernández Aguado I; McMenamin J; Zangerle R; Fontanet A; Coutinho RA; Prins M
    Eur J Public Health; 2003 Dec; 13(4):347-9. PubMed ID: 14703322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001.
    García de la Hera M; Ferreros I; del Amo J; García de Olalla P; Pérez Hoyos S; Muga R; del Romero J; Guerrero R; Hernández-Aguado I;
    J Epidemiol Community Health; 2004 Nov; 58(11):944-50. PubMed ID: 15483312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men.
    Prins M; Sabin CA; Lee CA; Devereux H; Coutinho RA
    AIDS; 2000 Aug; 14(12):1829-37. PubMed ID: 10985321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of education on overall and cause-specific mortality in injecting drug users, according to HIV and introduction of HAART.
    Jarrin I; Lumbreras B; Ferreros I; Pérez-Hoyos S; Hurtado I; Hernández-Aguado I
    Int J Epidemiol; 2007 Feb; 36(1):187-94. PubMed ID: 17085455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival and progression to AIDS in a seroconverter cohort in the post-highly active antiretroviral therapy era: effectiveness goes on.
    Pérez-Hoyos S; Ferreros I; del Amo J; Muga R; del Romero J; de Olalla PG; Hernández-Aguado I
    AIDS; 2006 Jan; 20(2):289-91. PubMed ID: 16511426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of survival following HIV-1 seroconversion after the introduction of HAART.
    Porter K; Babiker A; Bhaskaran K; Darbyshire J; Pezzotti P; Porter K; Walker AS;
    Lancet; 2003 Oct; 362(9392):1267-74. PubMed ID: 14575971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women.
    Jarrin I; Geskus R; Bhaskaran K; Prins M; Perez-Hoyos S; Muga R; Hernández-Aguado I; Meyer L; Porter K; del Amo J;
    Am J Epidemiol; 2008 Sep; 168(5):532-40. PubMed ID: 18663213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy.
    Mocroft A; Gatell J; Reiss P; Ledergerber B; Kirk O; Vella S; Blaxhult A; Phillips AN; Lundgren J;
    AIDS; 2004 Nov; 18(17):2333-7. PubMed ID: 15577550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initiation, changes in use and effectiveness of highly active anti-retroviral therapy in a cohort of injecting drug users.
    Egea JM; Muga R; Sirera G; Clotet B; Tor J; Ardèvol M; Rey-Joly C; Muñoz A
    Epidemiol Infect; 2002 Oct; 129(2):325-33. PubMed ID: 12403108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do HIV disease progression and HAART response vary among injecting drug users in Europe?
    van Asten L; Zangerle R; Hernández Aguado I; Boufassa F; Broers B; Brettle RP; Roy Robertson J; McMenamin J; Coutinho RA; Prins M
    Eur J Epidemiol; 2005; 20(9):795-804. PubMed ID: 16170664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Access to highly active antiretroviral therapy (HAART) for injecting drug users in the WHO European Region 2002-2004.
    Donoghoe MC; Bollerup AR; Lazarus JV; Nielsen S; Matic S
    Int J Drug Policy; 2007 Aug; 18(4):271-80. PubMed ID: 17689375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users.
    Prins M; Hernández Aguado IH; Brettle RP; Robertson JR; Broers B; Carré N; Goldberg DJ; Zangerle R; Coutinho RA; van den Hoek A
    AIDS; 1997 Nov; 11(14):1747-56. PubMed ID: 9386810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Universal access to HIV/AIDS treatment for injecting drug users: keeping the promise.
    Ball AL
    Int J Drug Policy; 2007 Aug; 18(4):241-5. PubMed ID: 17689371
    [No Abstract]   [Full Text] [Related]  

  • 14. Progression to AIDS slowed even more after the first two years with highly active antiretroviral therapy.
    Amundsen EJ; Fekjaer H
    Scand J Public Health; 2003; 31(4):312-8. PubMed ID: 15099038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of heroin and cocaine injection and plasma HIV-1 RNA suppression among a long-term cohort of injection drug users.
    Kerr T; Marshall BD; Milloy MJ; Zhang R; Guillemi S; Montaner JS; Wood E
    Drug Alcohol Depend; 2012 Jul; 124(1-2):108-12. PubMed ID: 22245312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of resistance to highly active antiretroviral therapy among HIV-positive injecting drug users: a meta-analysis.
    Werb D; Mills EJ; Montaner JS; Wood E
    Lancet Infect Dis; 2010 Jul; 10(7):464-9. PubMed ID: 20610328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: a nationwide population-based cohort study.
    Larsen MV; Omland LH; Gerstoft J; Røge BT; Larsen CS; Pedersen G; Obel N; Kronborg G
    Scand J Infect Dis; 2010 Dec; 42(11-12):917-23. PubMed ID: 20840000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral HIV treatment and care for injecting drug users: an evidence-based overview.
    Lert F; Kazatchkine MD
    Int J Drug Policy; 2007 Aug; 18(4):255-61. PubMed ID: 17689373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].
    Pezzotti P; Dorrucci M; Donisi A; Cusini M; Mazzarello G; De Luca A; Salassa B; Ursitti MA; Giuliani M; Rezza G;
    Epidemiol Prev; 2003; 27(6):348-55. PubMed ID: 15058363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
    Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
    Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.